CBDY Target Group Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1586554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY-155.4%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR40.5%
Net income 3-yr CAGR—
Margins
Gross margin42.0%
Operating margin—
Net margin-30.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-24.6%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets245.5%
Debt / equity—
Current ratio0.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.01M | $1.38M | $879,442 | $735,190 | $499,650 | $1.25M | $1.40M | $1.86M |
| Cost of revenue | $1.02M | $752,520 | $687,655 | $447,991 | $235,291 | $500,303 | $629,612 | $777,447 |
| Gross profit | $994,062 | $628,318 | $191,787 | $287,199 | $264,359 | $745,421 | $770,827 | $1.08M |
| Interest expense | $288,740 | $289,170 | $288,249 | $262,767 | $266,716 | $263,970 | $250,766 | $263,002 |
| Pretax income | -$168,281 | -$239,812 | -$550,356 | -$552,307 | -$479,392 | -$219,770 | -$108,213 | $215,958 |
| Net income | -$168,281 | -$239,812 | -$550,356 | -$552,307 | -$479,392 | -$219,770 | -$108,213 | $215,958 |
| EPS (basic) | -0.00 | -0.00 | -0.00 | — | -0.00 | -0.00 | -0.00 | — |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | — | -0.00 | -0.00 | -0.00 | — |
| Weighted avg. shares (diluted) | 617.03M | 617.03M | 617.03M | — | 617.03M | 617.03M | 617.03M | — |
| Banking | ||||||||
| Loans, net | — | — | — | — | — | $73,300 | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $189,235 | $14,006 | $209,897 | $108,800 | $345,748 | $845,927 | $781,703 | $1.88M |
| Receivables | $1.12M | $522,374 | $454,765 | $446,283 | $312,541 | $311,894 | $645,564 | $77,092 |
| Inventory | $1.46M | $1.72M | $1.68M | $1.67M | $1.42M | $1.67M | $1.67M | $882,279 |
| Current assets | $2.91M | $2.37M | $2.48M | $2.33M | $2.18M | $2.31M | $2.41M | $3.10M |
| PP&E, net | $2.89M | $3.03M | $3.31M | $3.55M | $3.73M | $3.98M | $3.97M | $4.19M |
| Goodwill | $251,178 | $250,786 | $255,668 | $260,016 | $255,989 | $261,228 | $247,899 | $247,685 |
| Total assets | $6.07M | $5.68M | $6.08M | $6.18M | $6.20M | $6.59M | $6.67M | $7.57M |
| Current liabilities | $14.22M | $13.60M | $13.82M | $13.38M | $12.74M | $9.97M | $12.34M | $13.10M |
| Short-term debt | $7.35M | $7.33M | $7.48M | $7.60M | $7.49M | $7.64M | $7.25M | $7.24M |
| Long-term debt | $7.35M | $7.33M | $7.48M | $7.60M | $7.49M | $7.64M | $7.25M | $7.24M |
| Total debt | $14.69M | $14.67M | $14.95M | $15.21M | $14.97M | $15.28M | $14.50M | $14.49M |
| Total liabilities | $14.90M | $14.33M | $14.62M | $14.24M | $13.63M | $13.62M | $13.29M | $14.08M |
| Shareholders' equity | -$8.83M | -$8.66M | -$8.54M | -$8.06M | -$7.43M | -$7.03M | -$6.62M | -$6.51M |
| Net debt | $14.50M | $14.65M | $14.74M | $15.10M | $14.63M | $14.43M | $13.72M | $12.61M |
| Shares outstanding | 617.03M | 617.03M | 617.03M | 617.03M | 617.03M | 617.03M | 617.03M | 617.03M |
| Cash flow statement | ||||||||
| Operating cash flow | $293,612 | -$222,908 | -$93,665 | -$250,788 | -$506,066 | $484,434 | -$570,005 | $736,437 |
| Investing cash flow | -$80,312 | -$6,516 | -$40,055 | $13,022 | $24,488 | $15,904 | $27,965 | -$50,094 |
| Financing cash flow | -$33,226 | $30,938 | $240,570 | -$682 | -$8,135 | -$498,557 | -$557,440 | $4,942 |
| Depreciation & amortization | $227,580 | $228,960 | $229,653 | $225,338 | $227,647 | $226,942 | $218,476 | $269,923 |
Free plan shows the latest 8 periods; Pro shows all 52 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.